Apellis Pharmaceuticals Receivables

Apellis Pharmaceuticals's receivables stands at $440M as of March 2026. That compares with $240M in the prior-year period — up 80.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Apellis Pharmaceuticals reported $440M in receivables versus $240M a year earlier — a 80.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $240M in the prior-year period — up 80.2% year over year. Sustained growth in receivables can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Apellis Pharmaceuticals's receivables evolved across reporting periods, while the comparison chart places APLS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, receivables is commonly used to spot outliers. Apellis Pharmaceuticals's reading of $440M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.